Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-14-006917
Filing Date
2014-09-25
Accepted
2014-09-25 17:26:04
Documents
1
Period of Report
2014-09-23

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f4092314seth_actinium.html 4  
1 OWNERSHIP DOCUMENT f4092314seth_actinium.xml 4 5293
  Complete submission text file 0001213900-14-006917.txt   6733
Mailing Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036
Business Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036 212-300-2131
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 300 E 93RD STREET, #20-B NEW YORK NY 10128
Business Address
SETH SANDESH (Reporting) CIK: 0001566175 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36374 | Film No.: 141121393